Physician profile
Kai Xia
NPI 1548236284
$26,107.48
in general payments reported to CMS, 2019-2025
23 companies · $13K in 2025
The $13K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,682 · 2020: $74.90 · 2021: $154 · 2022: $216 · 2023: $169 · 2024: $11K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $2,634 · Travel and Lodging: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,740.50 |
| Food and Beverage | $2,634.33 |
| Travel and Lodging | $1,606.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $22,687.19 | 2024-2025 | Rezdiffra |
| Echosens North America, INC. | $1,007.19 | 2019 | |
| Gilead Sciences, INC. | $656.24 | 2019-2025 | |
| Medtronic, INC. | $326.31 | 2022-2025 | Gi Genius, Pillcam, Endoflip |
| Micro-Tech Endoscopy USA, INC. | $302.62 | 2021-2025 | |
| Abbvie INC. | $270.80 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $237.91 | 2024 | Stelara, Remicade, Tremfya |
| Qol Medical, LLC | $148.42 | 2019-2024 | Sucraid |
| Erbe USA INC | $92.27 | 2019 | |
| Covidien Lp | $61.31 | 2019 | |
| Allergan, INC. | $52.77 | 2019 | |
| Novo Nordisk INC | $46.30 | 2025 | |
| Boston Scientific Corporation | $31.76 | 2023-2025 | Apollo 2-0 Polypropylene Endobariatric Suture |
| Shionogi INC | $29.79 | 2019-2020 | |
| Braintree Laboratories, INC. | $27.50 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $26.98 | 2020-2024 | Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.18 | 2019 | |
| Shire North American Group INC | $17.21 | 2019 | |
| Mirum Pharmaceuticals, INC. | $14.19 | 2025 | Cholbam, Livmarli, Chenodal |
| Merck Sharp & Dohme LLC | $13.70 | 2019 | |
| Ethicon US, LLC | $13.25 | 2019 | |
| Dynavax Technologies Corporation | $12.36 | 2019 | |
| Janssen Biotech, INC. | $5.23 | 2024 | Stelara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kai Xia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.